Cholexit offers a convenient way for self-treatment of high cholesterol.
NEWS RELEASE
12.02. 2004 at 15.00
Cholexit offers a convenient way for self-treatment of high cholesterol
Cholexit is a new over-the-counter product to lower high blood cholesterol. High blood cholesterol is the number one health risk in Finland. 68% of the Finnish population suffer from high blood cholesterol (according to Finnish Public Health Institute, FINRISK 2002-research).
Cholexit offers an easy solution to high blood cholesterol. Unlike other cholesterol-lowering products. Cholexit is available in handy caplets. This is an obvious advantage to current fat-spread-based products. Cholexit is available through pharmacies starting from 1.3.2004.
The active ingredient of Cholexit is the Reducol plant stanol and sterol preparation. The benefits of plant stanols and sterols have been scientifically proven in numerous clinical trials.
Reducol is an internationally researched and approved product. The US (FDA / GRAS) and EU (EFSA) officials have recognised Reducol as safe and effective in lowering cholesterol. Reducol™-trademark and patents are the property of Forbes Medi-Tech Inc. (www.forbesmedi.com).
Cholexit and cholesterol lowering drugs work well together
More than 300 000 Finns receive governmental subsidies for cholesterol lowering drugs. The effect of Cholexit is additive to the effect of cholesterol lowering drugs, since Cholexit blocks the absorption of cholesterol during digestion; whereas cholesterol-lowering drugs (statins) act by blocking cholesterol production within the liver. Due to its function mechanism, Cholexit suits patients, who for some reason (i.e. liver disease) cannot use cholesterol-lowering drugs. Cholexit is lactose free, and is suitable for diabetics.
Scanvit Ltd
Cholexit is manufactured in Finland by Pharmia Ltd. Cholexit is distributed and marketed to pharmacies through Tamro Finland / Pharmakon. Cholexit trademark is the property of Scanvit Ltd, the exclusive representative of Reducol in Finland, Scandinavia and selected European countries. Scanvit Ltd. is a privately held Finnish health-care company focusing on the prevention of cardiovascular diseases.
More information | Scanvit Ltd. | +358 9 6767 99 | |
managing director | Perttu Rönkkö | +358 50 537 2722 | |
sales and marketing | Miku Santavirta | +385 400 4433 43 |